ClinicalTrials.gg
RecruitingNCT05460975Updated Jun 4, 2024

Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study)

An observational study in Breast Cancer and Screening, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to female participants aged 40 Years to 69 Years. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Seoul National University Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16,164
Ages
40 Years to 69 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Breast Neoplasms by Seoul National University Hospital — 13 open to participants now, 21 under way, 3 of them phase 3. Breast Neoplasms · Seoul National University Hospital.

Planned enrollment
Largest of 22
16,164 · median 352
Started
2022
with 7 others
Observational
22 of 50
5 open now
Primary completion
2026-03
later than 11 of 20 live
Registered
41st of 50
by date

Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, this one has the largest planned enrollment of the 22 observational ones that give a count, is one of 8 that started in 2022, is one of 22 observational ones, reaches primary completion later than 11 of the 20 other live ones, and was the 41st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 50 studies in Breast Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 69 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Breast Neoplasms by Seoul National University Hospital, or all of them as a file.
02

Study summary

An international multicenter study to prospectively validate the association between sonographic GTC and subsequent breast cancer risk in women with dense breasts.

Read the detailed description

Women with similarly dense breasts on mammography may have different subsequent risks of developing breast cancer due to varying degrees of lobular involution. Breast ultrasound (US) can assess the relative amount of glandular tissue component (GTC) to the fibrous stroma in dense breast parenchyma and can reflect the amount of terminal duct lobular units (TDLU) as seen in histology. In women with dense breasts on mammography, an association between high levels of sonographic GTC, defined as the percent of glandular tissue within fibroglandular tissue, and an increased risk of breast cancer was demonstrated in a retrospective single-center study of 8483 Korean women. The purpose of this international multicenter study is to prospectively validate whether sonographic GTC is associated with subsequent breast cancer risk and whether it can provide additional information beyond established risk factors. In this study, investigators will enroll 16164 women with dense breasts (BI-RADS density categories C and D on mammography) undergoing screening breast US using either an automated or handheld device. GTC will be assessed qualitatively as minimal, mild, moderate, or marked at the time of US interpretation and will be dichotomized into low (minimal or mild) versus high (moderate or marked). The primary outcome is a pathologic diagnosis of breast cancer, including invasive cancer and ductal carcinoma in situ (DCIS). Women are observed from 3 months after date of GTC assessment to breast cancer diagnosis or censoring as a result of death or end date of complete cancer capture. Covariate information will be obtained from self-report at the time of breast US examination and includes age, race/ethnicity, menopausal status, first-degree family history of breast cancer, breast density, history of benign breast biopsy, BMI, age at first live birth, and hormone replacement therapy (HRT) usage. The 5-year cumulative incidence of breast cancer by level of sonographic GTC will be compared based on marginal standardization with the predicted risk summed to a weighted risk according to the observed covariate distribution in the study population. The association of sonographic GTC with breast cancer risk will be estimated by using the Fine-Gray subdistribution hazards model to account for the competing risk of death. In addition, investigators will compare the discriminatory accuracy of the breast cancer surveillance consortium (BCSC) 5-year risk score and the BCSC model integrated with sonographic GTC.

03

Conditions studied

  • Breast Cancer
  • Screening

Browse trials for

Keywords

  • Breast cancer
  • Dense breast
  • Risk factors
  • Ultrasonography
04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

16164 women

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. be ≥ 40 and \<70 years old at time of US
  2. No history of previous breast cancer including DCIS
  3. have dense breasts (BI-RADS category C and D on mammography performed within 12 months of breast US) and negative/benign BI-RADS assessment categories on mammography (BI-RADS 1, 2)
  4. undergoing screening breast US using either automated or handheld device

Exclusion criteria

Exclusion Criteria

  1. history of bilateral prophylactic mastectomy
  2. history of bilateral foreign body injection
  3. history of bilateral breast implants
  4. history of bilateral breast reduction surgery or surgical excision
  5. currently pregnant or breast feeding in the preceding 6 months
  6. Known distant from other primary cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16,164 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incident breast cancer within 3 months to 7 years after the assessment of sonographic GTC

    The 5-year cumulative incidence of breast cancer and hazard ratio by level of sonographic GTC using standardized risk

    Time frame: from 3 months to 7 years after the GTC assessment

Secondary outcomes

  1. Correlation of sonographic GTC with risk according to tumor type

    Correlation of sonographic GTC with risk according to tumor type (DCIS vs. invasive cancer)

    Time frame: from 3 months to 7 years after the GTC assessment

  2. Correlation of sonographic GTC with breast cancer according to the breast US device

    Correlation of sonographic GTC with breast cancer according to the breast US device (hand-held vs. automated)

    Time frame: from 3 months to 7 years after the GTC assessment

  3. The expected-to-observed (E/O) number of cancer diagnoses and concordance index (discriminatory accuracy)

    The expected-to-observed (E/O) number of cancer diagnoses and concordance index (discriminatory accuracy) for the BCSC model (5-year risk score) and BCSC model integrated with sonographic GTC

    Time frame: from 3 months to 7 years after the GTC assessment

  4. Breast US diagnostic performance according to sonographic GTC

    Sensitivity, specificity, positive predictive value

    Time frame: from the examination till 1 year after the GTC assessment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lee SH, Moon WK. Glandular Tissue Component on Breast Ultrasound in Dense Breasts: A New Imaging Biomarker for Breast Cancer Risk. Korean J Radiol. 2022 Jun;23(6):574-580. doi: 10.3348/kjr.2022.0099. No abstract available. PubMed 35617993 ↗
  • Lee SH, Ryu HS, Jang MJ, Yi A, Ha SM, Kim SY, Chang JM, Cho N, Moon WK. Glandular Tissue Component and Breast Cancer Risk in Mammographically Dense Breasts at Screening Breast US. Radiology. 2021 Oct;301(1):57-65. doi: 10.1148/radiol.2021210367. Epub 2021 Jul 20. PubMed 34282967 ↗
  • Acciavatti RJ, Lee SH, Reig B, Moy L, Conant EF, Kontos D, Moon WK. Beyond Breast Density: Risk Measures for Breast Cancer in Multiple Imaging Modalities. Radiology. 2023 Mar;306(3):e222575. doi: 10.1148/radiol.222575. Epub 2023 Feb 7. PubMed 36749212 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Mar 2026, 40 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 40 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2022
First posted
Jul 15, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Mar 30, 2026
CompletionEst.
Dec 30, 2031
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05460975
Responsible party
Woo Kyung Moon (Principal Investigator, Seoul National University Hospital) — Principal investigator
First posted
Jul 15, 2022
Start date
Nov 1, 2022
Primary completion
Mar 30, 2026 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Jun 4, 2024

Study contacts

Woo Kyung Moon, MD, PhD
Contact
moonwk1963@gmail.com
+82220722584
Woo Kyung Moon, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion